Supernus Announces Third Quarter 2022 Financial Results
November 08, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million...
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
October 25, 2022 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Update on SPN-830
October 10, 2022 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
August 31, 2022 16:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2022 Financial Results
August 04, 2022 16:01 ET
|
Supernus Pharmaceuticals, Inc.
Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating...
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
July 25, 2022 17:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the Jefferies Healthcare Conference
June 02, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2022 Financial Results
May 09, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43,...
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
May 02, 2022 16:55 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
April 29, 2022 20:00 ET
|
Supernus Pharmaceuticals, Inc.
First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,...